Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-RCHP-X vs RCHOP-X vs Pola-RCHP in Previously Untreated DLBCL
NCT06516978Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, randomised, open-label trial of polatuzumab vedotin, orelabrutinib, tucidinostat, venetoclax, lenalidomide and 1 more in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression Free Survival at 24 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
polatuzumab vedotinorelabrutinibtucidinostatvenetoclaxlenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06516978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516978.